Skip to Content

Conray (iothalamate) Disease Interactions

There are 5 disease interactions with Conray (iothalamate):

Major

Radiopaque Contrast Agents (Includes Conray) ↔ Pheochromocytoma

Severe Potential Hazard, Moderate plausibility

Applies to: Pheochromocytoma

Administration of radiopaque materials to patients known or suspected of having pheochromocytoma should be performed with extreme caution. If, in the opinion of the physician, the possible benefits of such procedures outweigh the considered risk, the procedures should be performed with the absolute minimum amount of injected radiopaque medium. The blood pressure should be assessed throughout the procedure and measures for treatment of a hypertensive crisis should be available.

Moderate

Contrast Agents (Includes Conray) ↔ Sickle Cell Disease

Moderate Potential Hazard, Moderate plausibility

Applies to: Sickle Cell Anemia

Some contrast agents have shown to promote the phenomenon of sickling (blood cell rupture) in individuals who are homozygous for sickle cell disease when administered intravenously or intra- arterially. Caution is advised.

Moderate

Iodinated Contrast Media (Includes Conray) ↔ Renal Disease

Moderate Potential Hazard, Moderate plausibility

Applies to: Renal Dysfunction, Kidney Transplant, Hypertension, Liver Disease, Congestive Heart Failure

In patients with advanced renal disease, iodinated contrast media should be used with caution, and only when the need for the examination dictates, since the excretion of the medium may be impaired. Patients with combined renal and hepatic disease, severe hypertension or congestive heart failure, and those with recent renal transplant may present an additional risk.

Moderate

Iodinated Radiopaque Contrast Agents (Includes Conray) ↔ Hyperthyroidism

Moderate Potential Hazard, Moderate plausibility

Applies to: Hyperthyroidism

Reports of thyroid storm following the use of iodinated diagnostic agents in patients with hyperthyroidism or with an autonomously functioning thyroid nodule suggest that this additional risk be evaluated in such patients before the use of any contrast medium.

Moderate

Iothalamate (Includes Conray) ↔ Subarachnoid Hemorrhage

Moderate Potential Hazard, Moderate plausibility

Applies to: Intracranial Hemorrhage

In patients with subarachnoid hemorrhage, a rare association between contrast administration and clinical deterioration, including seizures and death has been reported. Administration of intravascular iodinated contrast media such as iothalamate in these patients should be undertaken with caution.

Conray (iothalamate) drug Interactions

There are 246 drug interactions with Conray (iothalamate)

Conray (iothalamate) alcohol/food Interactions

There is 1 alcohol/food interaction with Conray (iothalamate)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2018 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide